The maturing immune system: Implications for development and testing HIV-1 vaccines for children and adolescents

AIDS

Volumn 20, Issue 4, 2006, Pages 483-494

  Jaspan, Heather B ^a   Lawn, Stephen D ^a,b   Safrit, Jeffrey T ^c   Bekker, Linda Gail ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CHICKENPOX VACCINE; DNA VACCINE; GAMMA INTERFERON; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; INTERLEUKIN 12; MALARIA VACCINE; MUMPS VACCINE; NEUTRALIZING ANTIBODY; POLYSACCHARIDE VACCINE; TOLL LIKE RECEPTOR; ANDROGEN; ESTROGEN;

ADOLESCENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; CHILD; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; VIRUS TRANSMISSION; AGE; CELLULAR IMMUNITY; GENE VECTOR; IMMUNOLOGY;

ADOLESCENT; AGE FACTORS; AIDS VACCINES; ANDROGENS; CHILD; ESTROGENS; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; IMMUNITY, CELLULAR;

EID: 33645412387     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000210602.40267.60     Document Type: Editorial

References (121)

1. Mwau M, McMichael AJ. A review of vaccines for HIV prevention. J Gene Med 2003; 5:3-10.
2. Graham B, Wright P. Candidate AIDS vaccines. New Engl J Med 1995; 333:1331-1339.
3. Graham BS, Mascola JR. Lessons from failure-preparing for future HIV-1 vaccine efficacy trials. J Infect Dis In Press.
4. The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (in press).
5. Parren PWHI, Wang M, Trkola A, Binley JM, Purtscher M, Katinger H, et al. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1. J Virol 1998; 72:10270-10274.
6. UNAIDS. AIDS Epidemic Update. 2004.
7. Jaspan HB, Garry RF. Preventing neonatal HIV: A review. Curr HIV Res 2003; 1:321-327.
8. Dunkle KL, Jewkes RK, Brown HC, Gray GE, McIntryre JA, Harlow SD. Transactional sex among women in Soweto, South Africa: prevalence, risk factors and association with HIV infection. Soc Sci Med 2004; 59:1581-1592.
9. Eaton L, Flisher AJ, Aaro LE. Unsafe sexual behaviour in South African youth. Soc Sci Med 2003; 56:149-165.
10. Kaaya SF, Flisher AJ, Mbwambo JK, Schaalma H, Aaro LE, Klepp KI. A review of studies of sexual behaviour of school students in sub-Saharan Africa. Scand J Public Health 2002; 30:148-160.
11. Kelly K, Ntlabati P. Early adolescent sex in South Africa: HIV intervention challenges. Social Dynamics - A Journal of the Centre for African Studies University of Cape Town 2002; 28:42-63.
12. Manzini N. Sexual initiation and childbearing among adolescent girls in KwaZulu Natal, South Africa. Reprod Health Matters 2001; 9:44-52.
13. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report 2002. 14.
14. Borkowsky W, Wara D, Fenton T, McNamara J, Kang MH, Mofenson L, et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. J Infect Dis 2000; 181:890-896.
15. Cunningham CK, Wara DW, Kang MH, Fenton T, Hawkins E, McNamara J, et al. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-Infected women. Clin Inf Dis 2001; 32:801-807.
16. Johnson D, McFarland E, Muresan P, Fenton T, Lambert J, McNamara J, et al. PACTG 326: A phase i/ii study to evaluate the safety and immunogenicity of alvac hiv vaccines alone and with AIDSVax B/B in children born to HIV-infected mothers: Preliminary Results. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 404].
17. McFarland E, Johnson D, Fenton T, Muresan P, McNamara J, Hawkins E, et al. A phase I/II study of the safety and immunogenicity of an HIV-1 ALVAC vaccine in infants born to HIV-infected mothers. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 99].
18. McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis 2001; 184:1331-1335.
19. Safrit JT. HIV vaccines in infants and children: Past trials, present plans and future perspectives. Curr Mol Med 2003; 3:303-312.
20. Andre FE. Summary of safety and efficacy data on a yeast-derived hepatitis-b vaccine. Am J Med 1989; 87:S14-S20.
21. Meheus A, Alisjahbana A, Vranckx R, Sukadi A, Usman A, Ngantung W, et al. Immunogenicity of a recombinant-DNA hepatitis-B vaccine in neonates. Postgrad Med J 1987; 63:139-141.
22. McClure CA, Gray G, Rybczyk GK, Wright PF. Challenges to conducting HIV preventative vaccine trials with adolescents. J Acquir Immune Defic Syndr 2004; 36:726-733.
23. Stanford PD, Monte DA, Briggs FM, Flynn PM, Tanney M, Ellenberg JH, et al. Recruitment and retention of adolescent participants in HIV research: Findings from the REACH (Reaching for Excellence in Adolescent Care and Health) project. J Adolesc Health 2003; 32:192-203.
24. Koup RA, Safrit JT, Cao YZ, Andrews CA, Mcleod G, Borkowsky W, et al. Temporal association of cellular immune-responses with the initial control of viremia in primary human-immunodeficiency-virus type-1 syndrome. J Virol 1994; 68:4650-4655.
25. Janeway CJr, Travers P, Walport M, Capra JD. Immunobiology: The immune system in health and disease. Fourth edn. London: Taylor & Francis Inc.; 1999.
26. Siegrist CA, Cordova M, Brandt C, Barrios C, Berney M, Tougne C, et al. Determinants of infant responses to vaccines in presence of maternal antibodies. Vaccine 1998; 16:1409-1414.
27. Siegrist CA, Barrios C, Martinez X, Brandt C, Berney M, Cordova M, et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice. Eur J Immunol 1998; 28:4138-4148.
28. Stein KE. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J Infect Dis 1992; 165:S49-S52.
29. Hassan J, Reen DJ. Reduced primary antigen-specific T-cell precursor frequencies in neonates is associated with deficient interleukin-2 production. Immunology 1996; 87:604-608.
30. Shearer WT, Rosenblatt HM, Gelman RS, Oymopito R, Plaeger S, Stiehm ER, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: The pediatric AIDS clinical trials group P1009 study. J AllergyClin Immunol 2003; 112:973-980.
31. Chheda S, Palkowetz KH, Garofalo R, Rassin DK, Goldman AS. Decreased interleukin-10 production by neonatal monocytes and T cells: Relationship to decreased production and expression of tumor necrosis factor-alpha and its receptors. Pediatr Res 1996; 40:475-483.
32. Lewis DB Prickett KS, Larsen A, Grabstein K, Weaver M, Wilson CB. Restricted production of interleukin 4 by activated human T cells. Proc Natl Acad Sci USA 2005, 85:9743-9747.
33. Lilic D, Cant AJ, Abinun M, Calvert JE, Spickett GP. Cytokine production differs in children and adults. Pediatr Res 1997; 42:237-240.
34. Hassan J, Reen DJ. T-cell function in the human newborn. Immunol Today 2000; 21:107-108.
35. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001; 19:3331-3346.
36. Upham JW, Lee PT, Holt BJ, Heaton T, Prescott SL, Sharp MJ, et al. Development of interleukin-12-producing capacity throughout childhood. Infect Immun 2002; 70:6583-6588.
37. Splawski JB, Lipsky PE. Cytokine regulation of immunoglobulin secretion by neonatal lymphocytes. J Clin Invest 1991; 88:967-977.
38. Jelinek DF, Splawski JB, Lipsky PE. The roles of interleukin-2 and interferon-gamma in human B-cell activation, growth and differentiation. Eur J Immunol 1986; 16:925-932.
39. Chiba Y, Higashidate Y, Suga K, Honjo K, Tsutsumi H, Ogra PL. Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection. J Med Virol 1989; 28:133-139.
40. Pikora CA, Sullivan JL, Panicali D, Luzuriaga K. Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med 1997; 185:1153-1161.
41. Marchant A, Appay V, van der Sande M, Dulphy N, Liesnard C, Kidd M, et al. Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest 2003; 111:1747-1755.
42. Vancikova Z. Mucosal immunity - basic principles, ontogeny, cystic fibrosis and mucosal vaccination. Curr Drug Targets Immune Endocr Metabol Disord 2002; 2:83-95.
43. Sizonenko PC, Paunier L. Hormonal changes in puberty III: Correlation of plasma dehydroepiandrosterone, testosterone, FSH, and LH with stages of puberty and bone age in normal boys and girls and in patients with Addison's disease or hypogonadism or with premature or late adrenarche. J Clin Endocrinol Metab 1975; 41:894-904.
44. Verthelyi D. Sex hormones as immunomodulators in health and disease. Int Immunopharmacol 2001; 1:983-993.
45. Stimson WH. Oestrogen and human T lymphocytes: presence of specific receptors in the T-suppressor/cytotoxic subset. Scand J Immunol 1998; 28:345-350.
46. Benten WPM, Stephan C, Wunderlich F. B cells express intracellular but not surface receptors for testosterone and estradiol. Steroids 2002; 67:647-654.
47. Beagley K, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol 2003; 38:13-22.
48. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Seriolo B, et al. Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 2004; 13:635-638.
49. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999; 103:282-288.
50. Shrier LA, Bowman FP, Lin M, Crowley-Nowick PA. Mucosal immunity of the adolescent female genital tract. J Adolesc Health 2003; 32:183-186.
51. Jones RK, Bulmer JN, Searle RF. Cytotoxic activity of endometrial granulated lymphocytes during the menstrual cycle in humans. Biol Reprod 1997; 57:1217-1222.
52. Gaillard RC, Spinedi E. Sex- and stress-steroids interactions and the immune system: Evidence for a neuroendocrine-immunological sexual dimorphism. Domest Anim Endocrinol 1998; 15:345-352.
53. Ben Nathan D, Padgett DA, Loria RM. Androstenediol and dehydroepiandrosterone protect mice against lethal bacterial infections and lipopolysaccharide toxicity. J Med Microbiol 1999; 48:425-431.
54. Wunderlich F, Maurin W, Benten WPM, Schmitt, Wrede HP. Testosterone impairs efficacy of protective vaccination against P. chabaudi malaria. Vaccine 1993; 11:1097-1099.
55. Mark A, Carlsson RM, Granstrom M. Subcutaneous versus intramuscular injection for booster DT vaccination of adolescents. Vaccine 1999; 17:2067-2072.
56. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. New Engl J Med 2002; 347:1652-1661.
57. Tollerud DJ, Ildstad ST, Brown LM, Clark JW, Blattner WA, Mann DL, et al. T-cell subsets in healthy teenagers - transition to the adult phenotype. Clin Immunol Immunopathol 1990; 56:88-96.
58. Rudy BJ, Wilson CM, Durako S, Moscicki AB, Muenz L, Douglas SD. Peripheral blood lymphocyte subsets in adolescents: a longitudinal analysis from the REACH project. Clin Diagn Lab Immunol 2002; 9:959-965.
59. Satoh T, Brown LM, Blattner WA, Maloney EM, Kurman CC, Nelson DL, et al. Serum neopterin, beta(2)-microglobulin, soluble interleukin-2 receptors, and immunoglobulin levels in healthy adolescents. Clin Immunol Immunopathol 1998; 88:176-182.
60. McFarland RD, Douek DC, Koup RA, Picker LJ. Identification of a human recent thymic emigrant phenotype. Proc Natl Acad Sci USA 2000; 97:4215-4220.
61. Glezen WP. Maternal vaccines. Prim Care 2001; 28:791.
62. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005; 11:S54-S62.
63. Holt PG, Macaubas C, Cooper D, Nelson DJ, McWilliam AS. Th-1/Th-2 switch regulation in immune responses to inhaled antigens - role of dendritic cells in the aetiology of allergic respiratory disease. Dendritic Cells in Fundamental and Clinical Immunology Vol 3 1997, 417:301-306.
64. Malhotra I, Mungai P, Wamachi A, Kioko J, Ouma JH, Kazura JW, et al. Helminth- and bacillus Calmette-Guerin-induced immunity in children sensitized in utero to filariasis and schistosomiasis. J Immunol 1999; 162:6843-6848.
65. Actor JK, Shirai M, Kullberg MC, Buller RML, Sher A, Berzofsky JA. Helminth infection results in decreased virus-specific CD8+ cytotoxic T-cell and Th1-Cytokine responses as well as delayed virus clearance. Proc Natl Acad Sci USA 1993; 90:948-952.
66. Kozlowski PA, Cuuvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1997; 65:1387-1394.
67. Mahon BP. The rational design of vaccine adjuvants for mucosal and neonatal immunization. Curr Med Chem 2001; 8:1057-1075.
68. Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL. J Immunol 2000; 165:6454-6462.
69. Mutwiri G, Bateman C, Baca-Estrada ME, Snider M, Griebel P. Induction of immune responses in newborn lambs following enteric immunization with a human adenovirus vaccine vector. Vaccine 2000; 19:1284-1293.
70. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, et al. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95:1128-1137.
71. Gans H, DeHovitz R, Forghani B, Beeler J, Maldonado Y, Arvin AM. Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine 2003; 21:3398-3405.
72. Kutlu NO, Akinci A, Sonmezgoz E, Temel I, Evliyaoglu E. The effects of androstenediol and dehydroepiandrosterone on the immune response to BCG at puberty. J Trop Pediatr 2003; 49:181-185.
73. Immunization of Adolescents: Recommendations And Reports. U.S. Department of Health and Human Services. MMWR 1996, 45:(RR13).
74. Van Rompay KKA, Greenier JL, Cole KS, Earl P, Moss B, Steckbeck JD, et al. Immunization of newborn rhesus macaques with Simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIV-mac251. J Virol 2003; 77:179-190.
75. Hofmann-Lehmann R, Vlasak J, Williams AL, Chenine AL, McClure HM, Anderson DC, et al. Live attenuated, nef-deleted SIV is pathogenic in most adult macaques after prolonged observation. AIDS 2003; 17:157-166.
76. Fiore AE, Shapiro CN, Sabin K, Labonte K, Darling K, Culver D, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003; 22:354-359.
77. Nalin DR, Kuter BJ, Brown L, Patterson C, Calandra GB, Werzberger A, et al. Worldwide Experience with the Cr326F-derived inactivated hepatitis-A virus-vaccine in pediatric and adult-populations - an overview. J Hepatol 1993; 18: S51-S55.
78. Eder G, Kollaritsch H. Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children. Vaccine 2003; 21:3575-3583.
79. Sei S, Sandelli SL, Theofan G, Ratto-Kim S, Kumagai M, Loomis-Price LD, et al. Preliminary evaluation of human immunodeficiency virus type 1 (HIV-1) immunogen in children with HIV-1 infection. J Infect Dis 1999; 180:626-640.
80. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of 4 conjugate haemophilus-influenzae type-b vaccines. J Pediatr 1992; 120:184-189.
81. Arthur LO, Bess JW, Urban RG, Strominger JL, Morton WR, Mann DL, et al. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 1995; 69:3117-3124.
82. Moss RB, Savary JR, Diveley JP, Jensen F, Carlo DJ. Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model. Immunology 2002; 106:549-553.
83. Moss RB, Diveley J, Jensen FC, Gouveia E, Carlo DJ. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA. J Hum Virol 2001; 4:39-43.
84. Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res 2003; 338:2539-2547.
85. Lepow M, Barkin R, Meier K, Zahradnik J, Berkowitz C, James D, et al. Studies of safety and immunogenicity of hemophilus-influenzae type-B polysaccharide diphtheria toxoid conjugate vaccine (Prp-D) in children 7-14 months of age. Pediatr Res 1985; 19:A299.
86. Srivastava IK, Ulmer JB, Barnett SW. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev Vaccines 2004; 3:S33-S54.
87. Dalessandro U, Leach A, Drakeley CJ, Bennett S, Olaleye BO, Fegan GW, et al. Efficacy trial of malaria vaccine Spf66 in Gambian infants. Lancet 1995; 346:462-467.
88. Alonso PL, Smith TA, Armstrong, Schellenberg JRM, Kitua AY, Masanja H, Hayes R, et al. Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum. J Infect Dis 1996; 174:367-372.
89. Urdaneta M, Prata A, Struchiner CJ, Tosta CE, Tauil P, Boulos M. Evaluation of SPf66 malaria vaccine efficacy in Brazil. Am J Trop Med Hygiene 1998; 58:378-385.
90. Gahery-Segard H, Pialoux G, Figueiredo S, Igea C, Surenaud M, Gaston J, et al. Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide-vaccine: Characterization of CD8(+)-T-cell epitopes recognized. J Virol 2003; 77:11220-11231.
91. Siegrist CA. Potential advantages and risks of nucleic acid vaccines for infant immunization. Vaccine 1997; 15:798-800.
92. Martinez X, Brandt C, Saddallah F, Tougne C, Barrios C, Wild F, et al. DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life. Proc Natl Acad Sci USA 1997; 94:8726-8731.
93. Barouch DH, Letvin NL. DNA vaccination for HIV-1 and SIV. Intervirology 2000; 43:282-287.
94. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EGT, et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85:911-919.
95. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, Gorgone DA, Lifton MA. Neutralizing antibodies and CD84+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 2004; 78:2666-2673.
96. Van Rompay KA, Abel K, Lawson JR, Singh RP, Schmidt KA, Evans T, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005; 38:124-134.
97. Tan ND, Davidson D. Comparative differences and combined effects of interleukin-8, leukotriene b-4, and platelet-activating-factor on neutrophil chemotaxis of the newborn. Pediatr Res 1995; 38:11-16.
98. Bartlett JA, Schleifer SJ, Demetrikopoulos MK, Delaney BR, Shiflett SC, Keller SE. Immune function in healthy adolescents. Clin Diagn Lab Immunol 1998; 5:105-113.
99. Adkins B. T-cell function in newborn mice and humans. Immunol Today 1999; 20:330-335.
100. Salio M, Dulphy N, Renneson J, Herbert M, McMichael A, Marchant A, et al. Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells. Int Immunol 2003; 15:1265-1273.
101. Adamski J, Ma ZD, Nozell S, Benveniste EN. 17 beta-estradiol inhibits class II major histocompatibility complex (MHC) expression: Influence on histone modifications and CBP recruitment to the class 11 MHC promoter. Mol Endocrinol 2004; 18:1963-1974.
102. Wira CR, Rossoll RM. Antigen-presenting cells in the female reproductive-tract - influence of sex-hormones on antigen presentation in the vagina. Immunology 1995; 84:505-508.
103. Carruba G, D'Agostino P, Miele M, Calabro M, Barbera C, Di Bella G, et al. Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells. J Cell Biochem 2003; 90:187-196.
104. Padgett DA, Loria RM, Sheridan JF. Endocrine regulation of the immune response to influenza virus infection with a metabolite of DHEA-androstenediol. J Neuroimmunol 1997; 78:203-211.
105. Kurt-Jones EA, Belko J, Yu C, Newburger PE, Wang J, Chan M, et al. The role of toll-like receptors in herpes simplex infection in neonates. J Infect Dis 2005; 191:746-748.
106. Maret A, Coudert JD, Garidou L, Foucras G, Gourdy P, Krust A, et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. Eur J Immunol 2003; 33:512-521.
107. Straub RH, Schuld A, Mullington J, Haack M, Scholmerich J, Pollmacher T. The endotoxin-induced increase of cytokines is followed by an increase of cortisol relative to dehydroepiandrosterone (DHEA) in healthy male subjects. J Endocrinol 2002; 175:467-474.
108. Hameed A, Fox WM, Kurman RJ, Hruban RH, Podack ER. Perforin expression in endometrium during the menstrual-cycle. Int J Gynecol Pathol 1995; 14:143-150.
109. Chelimo K, Sumba PO, Kazura JW, Ofula AV, John CC. Interferon-gamma responses to Plasmodium falciparum liver-stage antigen-1 and merozoite-surface protein-1 increase with age in children in a malaria holoendemic area of western Kenya. Malar J 2003; 2:37.
110. Mustafa A, Nyberg F, Mustafa M, Bakhiet M, Mustafa E, Winblad B, et al. Growth hormone stimulates production of interferon-gamma by human peripheral mononuclear cells. Hormone Res 1997; 48:11-15.
111. South MA. IgA in neonatal immunity. Annals New York Acad Sci 1971; 176:40.
112. Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999; 42:93-106.
113. Ye P, Kirschner DE. Measuring emigration of human thymocytes by T-cell receptor excision circles. Crit Rev Immunol 2002; 22:483-497.
114. Christenson B, Bottiger M. Vaccination against measles, mumps and rubella (MMR) - a comparison between the antibody-responses at the ages of 18 months and 12 years and between different methods of antibody titration. J Biol Stand 1985; 13:167-172.
115. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Milman J, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004; 364: 1411-1420.
116. Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, Kester KE, et al. Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927-1934.
117. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004; 199:201-216.
118. Siegrist CA, Saddallah F, Tougne C, Martinez X, Kovarik J, Lambert PH. Induction of neonatal TH1 and CTL responses by live viral vaccines: a role for replication patterns within antigen presenting cells? Vaccine 1998; 16:1473-1478.
119. Ota MOC, Vekemans J, Schlegel-Haueter SE, Fielding K, Sanneh M, Kidd M, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168:919-925.
120. Fridkis-Hareli M, Reinherz EL. New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccination. Med Immunol 2004; 3.
121. Gupta RK, Chang AC, Siber GR. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems. Modulation of the immune response to vaccine antigens 1998; 92:63-78.